Who We Are
Nouveau Biosciences is composed of an unprecedented team of leaders combining business, science and regulatory expertise transforming oncology drug discovery, development and clinical application into approved therapies.
What We Do
We are pioneering novel technology for developing new drugs rapidly and effectively and are creating powerful, targeted medicines to treat cancer.
We have a clinic-ready lead asset, based on clinically validated chemistry and biology, with a potential rapid path to market entry. Our technology is capable of generating nearly unlimited de-risked, IP-protected assets that yield long-term value generation.
Cancer Therapies
Killing cancer cells is easy, but killing only the cancer cells is the critical challenge for improving patient outcomes and safety.
By unlocking the potential of established chemistry and biology by improving pharmacology, tolerability, and precision we are creating the biggest near-term opportunity in the oncology sector.
See a full presentation here of how we are revolutionizing highly effective cancer treatments for the most challenging forms of cancer.
Why Nouveau?
Nouveau is solving for the biggest challenges in oncology today.
We are poised for significant near-term and long-term value creation and have a clinic-ready program supported by compelling preclinical and clinical safety with best-in-disease activity in pancreatic cancer, AML and T-cell malignancies. Our program is inherently de-risked, offering multiple paths to rapid market entry.
Our follow-on pipeline of potential first & best-in-class candidates target validated tumor-specific biology and are supported by compelling clinical evidence. Nouveau’s proprietary technology enables an ongoing stream of enhanced first-in-class cancer therapeutics with strong IP protection.
Our Science
Nouveau Bioscience’s nanomedicine is unique and introduces ground-breaking approaches in improving the tolerability and efficacy of anti-cancer drugs. Our co-polymer nanoparticles can accommodate most drugs and drug combinations. Polymer nanoparticles are tailored to the drugs and exponentially expand opportunity for increased efficacy. Our nanoparticles can be bio-conjugated to enhance homing to the cancer.